[go: up one dir, main page]

HUP9800541A1 - Hipolipémiás hatású 1,4-benzotiazepin-1,1-dioxid-származékok, eljárás előállításukra, intermedierjeik és vegyületeket tartalmazó gyógyszerkészítmények - Google Patents

Hipolipémiás hatású 1,4-benzotiazepin-1,1-dioxid-származékok, eljárás előállításukra, intermedierjeik és vegyületeket tartalmazó gyógyszerkészítmények

Info

Publication number
HUP9800541A1
HUP9800541A1 HU9800541A HUP9800541A HUP9800541A1 HU P9800541 A1 HUP9800541 A1 HU P9800541A1 HU 9800541 A HU9800541 A HU 9800541A HU P9800541 A HUP9800541 A HU P9800541A HU P9800541 A1 HUP9800541 A1 HU P9800541A1
Authority
HU
Hungary
Prior art keywords
pipe powder
pipe
alkyl
carbon
powder
Prior art date
Application number
HU9800541A
Other languages
English (en)
Inventor
Alfons Enhsen
Eugen Falk
Heiner Glombik
Siegfried Stengelin
Original Assignee
Hoechst Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag. filed Critical Hoechst Ag.
Publication of HU9800541D0 publication Critical patent/HU9800541D0/hu
Publication of HUP9800541A1 publication Critical patent/HUP9800541A1/hu
Publication of HUP9800541A3 publication Critical patent/HUP9800541A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/007—Vector systems having a special element relevant for transcription cell cycle specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

A találmány tárgyát képezik új, (I) általánős képletű vegyületek,eljárás előállításűkra, új intermedierek és vegyületeket tartalmazógyógyszerkészítmények. A találmány szerinti vegyületek (I) általánősképletében R1 jelentése 1-6 szénatőmős egyenesláncú alkilcsőpőrt, R2jelentése 1-6 szénatőmős egyenesláncú alkilcsőpőrt, R3 jelentésehidrőgénatőm vagy OR11 csőpőrt, ahől R11 jelentése hidrőgénatőm, adőttesetben szűbsztitűált 1-6 szénatőmős alkilcsőpőrt vagy 1-6 szénatőmősalkil-karbőnil-csőpőrt, R4 jelentése piridilcsőpőrt vagy adőtt esetbenszűbsztitűált fenilcsőpőrt, R5, R6 és R8 jele lehet azőnős vagykülönböző, és a következők közül választható: hidrőgénatőm,halőgénatőm, cianőcsőpőrt, R15-acetilid, OR15, adőtt esetbenszűbsztitűált 1-6 szénatőmős alkilcsőpőrt, COR15, CH(OH)R15, S(O)nR15,P(O)(OR15)2, OCOR15, OCF3, OCN, SCN, NHCN, CH2OR15, CHO, (CH2)pCN,CONR12R13, (CH2)pCO2R15, (CH2)pNR12R13, CO2R15, NHCOCF3, NHSO2R15,OCH2OR15, OCH=CHR15, O(CH2CH2O)nR15, O(CH2)pSO3R15, O(CH2)pNR12R13 ésO(CH2)pN+R12R13R14, ahől p jelentése 1-től 4-ig terjedő egész szám, njelentése 0-tól 3-ig terjedő egész szám és R12, R13, R14 és R15jelentése egymástól függetlenül hidrőgénatőm vagy adőtt esetbenszűbsztitűált 1-6 szénatőmős alkilcsőpőrt, R7 jelentése (a) vagy (b)általánős képletű csőpőrt, ahől a hidrőxilcsőpőrtők adőtt esetbenacetilcsőpőrttal vagy benzilcsőpőrttal szűbsztitűáltak vagy -(C1-C6)-alkil-R17, ahől az alkilcsőpőrt adőtt esetben egy vagy többhidrőxilcsőpőrttal szűbsztitűált, R16 jelentése -COOH, -CH2-OH, -CH2-O-acetil, -COOMe vagy -COOEt, R17 jelentése H, -OH, -NH2, -COOH vagy -COOR18, R18 jelentése 1-4 szénatőmős alkilcsőpőrt vagy 1-4 szénatőmősalkil-aminő-csőpőrt, X jelentése -NH- vagy -O- és R9 és R10 jelentéseazőnősan vagy különbözően hidrőgénatőm vagy 1-6 szénatőmősalkilcsőpőrt. ŕ
HU9800541A 1997-03-14 1998-03-12 1,4-benzothiazepine-1,1-dioxides as hypolipidemics, process for HUP9800541A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97104348 1997-03-14

Publications (3)

Publication Number Publication Date
HU9800541D0 HU9800541D0 (en) 1998-05-28
HUP9800541A1 true HUP9800541A1 (hu) 1999-06-28
HUP9800541A3 HUP9800541A3 (en) 2000-08-28

Family

ID=8226598

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9800541A HUP9800541A3 (en) 1997-03-14 1998-03-12 1,4-benzothiazepine-1,1-dioxides as hypolipidemics, process for

Country Status (23)

Country Link
US (2) US6020330A (hu)
EP (1) EP0864582B1 (hu)
JP (1) JP3282998B2 (hu)
KR (1) KR19980080223A (hu)
CN (1) CN1070484C (hu)
AR (1) AR011189A1 (hu)
AT (1) ATE242258T1 (hu)
AU (1) AU731575B2 (hu)
BR (1) BR9801126A (hu)
CA (1) CA2231971C (hu)
CZ (1) CZ75998A3 (hu)
DE (1) DE69815180T2 (hu)
DK (1) DK0864582T3 (hu)
ES (1) ES2198613T3 (hu)
HU (1) HUP9800541A3 (hu)
ID (1) ID20053A (hu)
IL (1) IL123648A (hu)
NZ (1) NZ329932A (hu)
PL (1) PL325363A1 (hu)
PT (1) PT864582E (hu)
RU (1) RU2179977C2 (hu)
TR (1) TR199800444A2 (hu)
ZA (1) ZA982140B (hu)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
US6268392B1 (en) 1994-09-13 2001-07-31 G. D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
US6262277B1 (en) * 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
DE69815180T2 (de) * 1997-03-14 2004-04-29 Aventis Pharma Deutschland Gmbh Hypolipidemische 1,4-Benzothiazepin-1,1-dioxide
KR20010102965A (ko) 1998-12-23 2001-11-17 윌리암스 로저 에이 심장혈관의 징후에 대한 회장 담즙산 수송 저해제 및담즙산 격리제의 병용
JP2002533413A (ja) 1998-12-23 2002-10-08 ジー．ディー．サール エルエルシー 心臓血管に適用するための回腸胆汁酸輸送阻害剤およびフィブリン酸誘導体の組み合わせ
DK1140185T3 (da) 1998-12-23 2003-09-29 Searle Llc Kombinationer af cholesterylestertransferhæmmere og galdesyre kompleksdannende forbindelser til hjertekar indikationer
KR20010099937A (ko) 1998-12-23 2001-11-09 윌리암스 로저 에이 심혈관 징후용 콜레스테릴 에스테르 전달 단백질 억제제및 피브르산 유도체의 조합물
EA200100704A1 (ru) * 1998-12-23 2002-02-28 Джи.Ди.Сирл Ллс Комбинация для применения по сердечно-сосудистым показаниям
ATE242007T1 (de) 1998-12-23 2003-06-15 Searle Llc Kombinationen von cholesteryl ester transfer protein inhibitoren und nicotinsäure derivaten für kardiovaskuläre indikationen
US6462091B1 (en) 1998-12-23 2002-10-08 G.D. Searle & Co. Combinations of cholesteryl ester transfer protein inhibitors and HMG coA reductase inhibitors for cardiovascular indications
EP1342475A1 (en) 1998-12-23 2003-09-10 G.D. Searle LLC. Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications
DE19916108C1 (de) * 1999-04-09 2001-01-11 Aventis Pharma Gmbh Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
GB9914745D0 (en) * 1999-06-24 1999-08-25 Knoll Ag Therapeutic agents
SE0000772D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab Chemical compounds
AU2001240115A1 (en) 2000-03-10 2001-09-24 Pharmacia Corporation Method for the preparation of tetrahydrobenzothiepines
AU2001247331A1 (en) * 2000-03-10 2001-09-24 Pharmacia Corporation Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
US20020183307A1 (en) * 2000-07-26 2002-12-05 Tremont Samuel J. Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake
EG26979A (en) 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
US20040077625A1 (en) * 2001-07-25 2004-04-22 Tremont Samuel J. Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake
GB0121337D0 (en) 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
GB0121621D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
CN1582151A (zh) 2001-09-08 2005-02-16 阿斯特拉曾尼卡有限公司 用于治疗高脂血症、具有回肠胆汁酸转运(ibat)抑制活性的苯并硫氮杂䓬和苯并硫杂二氮杂䓬衍生物
JP2005518347A (ja) * 2001-11-02 2005-06-23 ジー．ディー． サール エルエルシー 頂端ナトリウム共依存性胆汁酸輸送（ａｓｂｔ）およびタウロコール酸塩取り込みの阻害剤としての新規一および二フッ化ベンゾチエピン化合物
EP1465885A4 (en) 2002-01-17 2005-04-27 Pharmacia Corp NOVEL ALKYL / ARYL HYDROXY OR CETOTHIEPINE COMPOUNDS AS INHIBITORS OF BILIARY ACID TRANSPORT OF THE ILEAL TYPE AND ABSORPTION OF TAUROCHOLATE
GB0201850D0 (en) * 2002-01-26 2002-03-13 Astrazeneca Ab Therapeutic treatment
GB0209467D0 (en) 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
GB0213669D0 (en) 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
US7312208B2 (en) 2002-08-28 2007-12-25 Asahi Kasei Pharma Corporation Quaternary ammonium compounds
GB0304194D0 (en) * 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
KR20070026392A (ko) 2004-02-27 2007-03-08 아사히 가세이 파마 가부시키가이샤 신규 벤조티아제핀 및 벤조티에핀 화합물
DE102005033099A1 (de) * 2005-07-15 2007-01-18 Sanofi-Aventis Deutschland Gmbh Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindung enthaltende Arzneimittel und dessen Verwendung
CN102316872B (zh) * 2008-11-26 2016-12-21 萨蒂奥根制药公司 治疗肥胖症和糖尿病的胆汁酸再循环抑制剂
EP3593802A3 (en) 2010-05-26 2020-03-25 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
BR112013010157B1 (pt) 2010-11-04 2020-02-04 Albireo Ab iinibidores do ibat, seus usos, e composição e combinações farmacêuticas
US20130236541A1 (en) 2010-11-08 2013-09-12 Albireo Ab Pharmaceutical combination comprising an ibat inhibitor and a bile acid binder
BR112014010223B8 (pt) 2011-10-28 2021-02-23 Lumena Pharmaceuticals Llc uso de uma composição compreendendo inibidores de reciclagem de ácido de bílis e forma de dosagem pediátrica
AU2012328453B2 (en) 2011-10-28 2017-05-04 Shire Human Genetic Therapies, Inc. Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease
BR112015023646A2 (pt) 2013-03-15 2017-07-18 Lumena Pharmaceuticals Inc inibidores de ácidos biliares de reciclagem para tratamento de colangite esclerosante primária e doença inflamatória do intestino
AU2014229050A1 (en) 2013-03-15 2015-10-22 Lumena Pharmaceuticals Llc Bile acid recycling inhibitors for treatment of Barrett's esophagus and gastroesophageal reflux disease
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
KR20220082931A (ko) 2014-06-25 2022-06-17 이에이 파마 가부시키가이샤 고형 제제 및 그의 착색 방지 또는 착색 감소 방법
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
RU2730524C2 (ru) * 2015-03-02 2020-08-24 Апейрон Биолоджикс Аг Бициклические тетрагидротиазепиновые производные, полезные для лечения неопластических и/или инфекционных заболеваний
RU2750944C2 (ru) 2016-02-09 2021-07-06 Альбирео Аб Пероральный состав холестирамина и его применение
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
EP3413878B1 (en) 2016-02-09 2021-04-14 Albireo AB Oral cholestyramine formulation and use thereof
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
CA3071182A1 (en) 2017-08-09 2019-02-14 Albireo Ab Cholestyramine pellets, oral cholestyramine formulations and use thereof
EP3664781A1 (en) 2017-08-09 2020-06-17 Albireo AB Cholestyramine granules, oral cholestyramine formulations and use thereof
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
EP3802504B1 (en) 2018-06-05 2023-01-18 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
PT3810581T (pt) 2018-06-20 2025-03-05 Albireo Ab Modificações cristalinas de odevixibat
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
CA3127408A1 (en) 2019-02-06 2020-08-13 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
AU2020218908B2 (en) 2019-02-06 2025-01-23 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
BR112021015799A2 (pt) 2019-02-12 2022-01-18 Mirum Pharmaceuticals Inc Métodos para aumentar o crescimento em pacientes pediátricos com doença colestática do fígado
AR120674A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzotiazepina y su uso como ácido biliar
WO2021110886A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
TWI877263B (zh) 2019-12-04 2025-03-21 瑞典商艾爾比瑞歐公司 苯并噻二氮呯化合物及其作為膽酸調節劑之用途
MX2022006731A (es) 2019-12-04 2022-06-09 Albireo Ab Compuestos de benzoti(di)azepina y su uso como moduladores del acido biliar.
HUE065571T2 (hu) 2019-12-04 2024-06-28 Albireo Ab Benzotia(di)azepin vegyületek és alkalmazásuk epesav modulátorként
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
CA3158181A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
ES2972045T3 (es) 2019-12-04 2024-06-10 Albireo Ab Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar
TWI867107B (zh) 2019-12-04 2024-12-21 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯化合物及其作為膽酸調節劑之用途
ES3029063T3 (en) 2019-12-04 2025-06-23 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
WO2022029101A1 (en) 2020-08-03 2022-02-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
CA3186857A1 (en) 2020-08-03 2022-02-10 Per-Goran Gillberg Benzothia(di)azepine compounds and their use as bile acid modulators
AU2021379076A1 (en) 2020-11-12 2023-06-08 Albireo Ab Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
WO2022101379A1 (en) 2020-11-12 2022-05-19 Albireo Ab Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
KR20230117393A (ko) 2020-12-04 2023-08-08 알비레오 에이비 벤조티아(디)아제핀 화합물 및 담즙산 조절제로서의용도
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
JP2025516153A (ja) 2022-04-22 2025-05-27 アルビレオ・アクチボラグ Ａｓｂｔ阻害剤の皮下投与
CN119343140A (zh) 2022-06-09 2025-01-21 阿尔比里奥公司 治疗肝炎
CN119487013A (zh) 2022-07-05 2025-02-18 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
AU2023374724A1 (en) 2022-11-03 2025-05-01 Albireo Ab Treating alagille syndrome (algs)
AU2023390975A1 (en) 2022-12-09 2025-06-05 Albireo Ab Asbt inhibitors in the treatment of renal diseases
WO2025093760A1 (en) 2023-11-03 2025-05-08 Albireo Ab Treating pfic2 with odevixibat
WO2025146508A1 (en) 2024-01-05 2025-07-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
WO2025146507A1 (en) 2024-01-05 2025-07-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9203347D0 (en) * 1992-02-17 1992-04-01 Wellcome Found Hypolipidaemic compounds
BR9307387A (pt) * 1992-11-09 1999-08-31 Boots Co Plc Agentes terapêuticos
IL108634A0 (en) * 1993-02-15 1994-05-30 Wellcome Found Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
ZA941003B (en) * 1993-02-15 1995-08-14 Wellcome Found Hypolipidaemic compounds
ZA956647B (en) * 1994-08-10 1997-02-10 Wellcome Found Hypolipidaemic compounds.
DE69815180T2 (de) * 1997-03-14 2004-04-29 Aventis Pharma Deutschland Gmbh Hypolipidemische 1,4-Benzothiazepin-1,1-dioxide

Also Published As

Publication number Publication date
CA2231971C (en) 2008-05-20
AU5834998A (en) 1998-09-17
ATE242258T1 (de) 2003-06-15
TR199800444A3 (tr) 1998-10-21
HU9800541D0 (en) 1998-05-28
JPH10279568A (ja) 1998-10-20
IL123648A0 (en) 1998-10-30
RU2179977C2 (ru) 2002-02-27
CA2231971A1 (en) 1998-09-14
CN1070484C (zh) 2001-09-05
HUP9800541A3 (en) 2000-08-28
ES2198613T3 (es) 2004-02-01
DK0864582T3 (da) 2003-09-29
US6114322A (en) 2000-09-05
EP0864582B1 (en) 2003-06-04
JP3282998B2 (ja) 2002-05-20
US6020330A (en) 2000-02-01
TR199800444A2 (xx) 1998-10-21
CN1194979A (zh) 1998-10-07
DE69815180T2 (de) 2004-04-29
PL325363A1 (en) 1998-09-28
AR011189A1 (es) 2000-08-02
ID20053A (id) 1998-09-17
IL123648A (en) 2000-11-21
EP0864582A2 (en) 1998-09-16
AU731575B2 (en) 2001-04-05
DE69815180D1 (de) 2003-07-10
ZA982140B (en) 1998-09-14
PT864582E (pt) 2003-10-31
CZ75998A3 (cs) 1998-09-16
EP0864582A3 (en) 1998-10-21
BR9801126A (pt) 2000-03-21
NZ329932A (en) 1999-01-28
KR19980080223A (ko) 1998-11-25

Similar Documents

Publication Publication Date Title
HUP9800541A1 (hu) Hipolipémiás hatású 1,4-benzotiazepin-1,1-dioxid-származékok, eljárás előállításukra, intermedierjeik és vegyületeket tartalmazó gyógyszerkészítmények
IL116002A0 (en) Substituted 3-arylidene-7-azaoxindole compounds their preparation and pharmaceutical compositions containing them
ATE12492T1 (de) Aryloxypropanolamine, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel.
UA76409C2 (uk) Трифенілалкенові похідні і їх застосування як селективних модуляторів рецепторів естрогену
NZ511739A (en) New esters derived from substituted phenyl-cyclohexyl compounds
CA2355075A1 (en) Heteroaryl-cyclic acetals
HUP9802865A2 (hu) N-(szubsztituált fenil-)-pirazol-származékok, előállításuk és alkalmazásuk, a vegyületeket hatóanyagként tartalmazó parazitaellenes készítmények
HUP9700992A2 (hu) 3-(Piperid-4-il)-1,2-benzizoxazol- és 3-(piperazin-4-il)-1,2-benzizoxazol-származékok, eljárás előállításukra, valamint ezeket tartalmazó gyógyászati készítmények
ES8301881A1 (es) Un procedimiento para la preparacion de derivados de ariletanolamina que tienen actividad antiobesidad yno hploglicemi- ca.
ES8307244A1 (es) Un procedimiento para la preparacion de nuevos derivados de benzamida.
HUP9802634A2 (hu) Benzimidazolok felhasználása leukémia kezelésére szolgáló gyógyszerkészítmények előállítására
ES8900270A1 (es) Procedimiento de producir agentes terapeuticos y profilacticos para ulceras pepticas
HUP9901969A2 (hu) N-(merkapto-alkanoil)-cisztein-származékok alkalmazása ischemia kezelésére szolgáló gyógyszerkészítmények előállítására
ES454668A1 (es) Procedimiento para la preparacion de nuevas homoftalimidas.
ZA868834B (en) New pyridine compounds with basic substituents,a process for their preparation,medicaments containing them,and their use
PT76335A (de) Neue basisch substituierte 4-phenyl-4,5,6,7-tetrahydro-thieno-<2,3-c>pyridine verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen
YU28902A (sh) Fenil- i piridil-tetrahidro-piridini koji imaju tnf-inhibitorsku aktivnost
PH12683A (en) 3-amino-1-phenyl-1h,5h-benzo-2,4-thiazepines and pharmaceutical compositions thereof
DK0412015T3 (da) Hidtil ukendte N-(23-vincristinoyl)- og N-(5-noranhydro-23-vinblastinoyl)-1-aminomethylphosphon- syrederivater, fremgangsmåde til fremstilling heraf og farmaceutiske midler, som indeholder dem
DK0395527T3 (da) Imidazobenzodiazepiner og deres salte, fremgangsmåde til deres fremstilling, deres anvendelse som lægemidler og præparater med indhold deraf
HUP0101046A2 (hu) Amiloidózis kezelésére alkalmazható amino-antraciklinon-származékok és ezeket tartalmazó gyógyszerkészítmények